USANA HEALTH SCIENCES INC USNA revenue by segment, product and geography
In its fiscal year ending 2025-12-31, USANA HEALTH SCIENCES INC reported revenue across 8 geographies; the largest, Asia Pacific, was $627M (-8.2% against the prior period in the same filing).
Reported segment mix
figures as filed · share of the filed sum · change vs the prior period in the same filing- Asia Pacific$627Mshare n/a-8.2% yoy
- Greater China$425Mshare n/a-7.3% yoy
- China$382Mshare n/a-7.7% yoy
- Americas And Europe$298Mshare n/a+73.8% yoy
- United States$225Mshare n/a+145.0% yoy
- Southeast Asia Pacific$132Mshare n/a-10.1% yoy
- North Asia$70.6Mshare n/a-9.7% yoy
- South Korea$68.9Mshare n/a-9.9% yoy
member sum exceeds the consolidated figure: this axis carries more than one breakdown, so shares are not computed.
- Asia Pacific$169Mshare n/a-2.3% yoy
- Greater China$123Mshare n/a+3.9% yoy
- China$113Mshare n/a+4.5% yoy
- Americas And Europe$80.9Mshare n/a+6.2% yoy
- United States$63.5Mshare n/a+9.7% yoy
- Southeast Asia Pacific$30.7Mshare n/a-14.2% yoy
- +1 more member in the filing
Change is against the same quarter a year earlier, as reported in the same 10-Q.
Source: SEC DERA Financial Statement and Notes data sets. Dimensional XBRL facts on the business-segment, product/service and geographic axes; the engine keeps the accession of every figure. Descriptive and educational, not advice.
About these figures
Companies tag segment, product and geographic revenue as dimensional XBRL facts in their 10-K and 10-Q filings. The SEC publishes those facts in its DERA Financial Statement and Notes data sets; TrendNalysis ingests each monthly file and serves the facts exactly as filed, keyed to the accession of the filing. Shares are of the filed sum. Where a filer tags more than one breakdown on one axis, the sum exceeds consolidated revenue and no shares are computed; where the members do not add up to the consolidated figure, the residual is stated rather than hidden. Missing is never zero.
Descriptive and educational; not investment advice. Methodology and data lineage.